# US 2024/0199609 A1 · Compounds and compositions for inhibiting the activity of shp2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199609 A1
- Document ID: US20240199609A1
- Status: Published application
- Kind: A1
- Application number: 18/523,565
- Filed: 2023-11-29
- Published: 2024-06-20
- Earliest claimed: 2016-06-14
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Zhuoliang CHEN; Jorge Garcia FORTANET; Rajesh KARKI; Matthew J. LAMARCHE; Dyuti MAJUMDAR; Lawrence Blas PEREZ; Martin SENDZIK; Troy Douglas SMITH; Fan YANG; Bing YU
- Web page: https://patentgrep.com/patent/US20240199609A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 455/02: containing not further condensed quinolizine ring systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim 10

A method of treating or preventing a disease or disorder that is mediated by the activity of SHP2 in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from:
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl, C1-3alkoxy and OC(O)C1-3alkyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R, is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R3 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH; and
Y5 is selected from N and CH; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 10)

The method of claim 10, wherein R1 is selected from the group consisting of:

### Claim 12 (depends on 10)

The method of claim 10, wherein R4 is hydroxyl.

### Claim 13 (depends on 10)

The method of claim 10, wherein R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, or 8-azaspiro[4.5]decan-8-yl; wherein said piperidinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, or 8-azaspiro[4.5]decan-8-yl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl.

### Claim 14 (depends on 10)

The method of claim 10, wherein R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, or 8-azaspiro[4.5]decan-8-yl; wherein said piperidinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, or 8-azaspiro[4.5]decan-8-yl is substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, and methyl-amino.

### Claim 15 (depends on 10)

The method of claim 10, wherein the compound of Formula I is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 10)

The method of claim 10, wherein the disease or disorder mediated by the activity of SHP2 is selected from the group consisting of Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.

### Claim 17

A method of treating or preventing a disease or disorder that is mediated by the activity of SHP2 in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound of Formula II:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is selected from:
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl, C1-3alkoxy and OC(O)C1-3alkyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH; and
Y5 is selected from N and CH.

### Claim 18 (depends on 17)

The method of claim 17, wherein:
R1 is selected from:
R4 is selected from hydroxyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y4 is selected from N and CH; and
Y5 is selected from N and CH.

### Claim 19 (depends on 17)

The method of claim 17, wherein R4 is hydroxyl.

### Claim 20 (depends on 17)

The compound of claim 17, or the pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 21 (depends on 17)

The compound of claim 17, or the pharmaceutically acceptable salt thereof, wherein R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a piperidinyl ring, wherein said piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl.

### Claim 22 (depends on 17)

The method of claim 17, wherein the compound of Formula II is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 23 (depends on 17)

The method of claim 17, wherein the disease or disorder mediated by the activity of SHP2 is selected from the group consisting of Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.

### Claim 24

A method of treating or preventing a disease or disorder that is mediated by the activity of SHP2 in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound having a structure selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 24)

The method of claim 24, wherein the disease or disorder mediated by the activity of SHP2 is selected from the group consisting of Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
